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Background No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant 
mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the 
efficacy and safety of nivolumab, an anti-PD-1 antibody, in these patients.
Methods This was a multicentre, placebo-controlled, double-blind, parallel group, randomised, phase 3 trial done in 
24 hospitals in the UK. Adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance 
status of 0 or 1, with histologically confirmed pleural or peritoneal mesothelioma, who had received previous first-line 
platinum-based chemotherapy and had radiological evidence of disease progression, were randomly assigned (2:1) to 
receive nivolumab at a flat dose of 240 mg every 2 weeks over 30 min intravenously or placebo until disease progression 
or a maximum of 12 months. The randomisation sequence was generated within an interactive web response system 
(Alea); patients were stratified according to epithelioid versus non-epithelioid histology and were assigned in random 
block sizes of 3 and 6. Participants and treating clinicians were masked to group allocation. The co-primary endpoints 
were investigator-assessed progression-free survival and overall survival, analysed according to the treatment policy 
estimand (an equivalent of the intention-to-treat principle). All patients who were randomly assigned were included 
in the safety population, reported according to group allocation. This trial is registered with Clinicaltrials.gov, 
NCT03063450.
Findings Between May 10, 2017, and March 30, 2020, 332 patients were recruited, of whom 221 (67%) were randomly 
assigned to the nivolumab group and 111 (33%) were assigned to the placebo group). Median follow-up was 
11·6 months (IQR 7·2–16·8). Median progression-free survival was 3·0 months (95% CI 2·8–4·1) in the nivolumab 
group versus 1·8 months (1·4–2·6) in the placebo group (adjusted hazard ratio [HR] 0·67 [95% CI 0·53–0·85; 
p=0·0012). Median overall survival was 10·2 months (95% CI 8·5–12·1) in the nivolumab group versus 6·9 months 
(5·0–8·0) in the placebo group (adjusted HR 0·69 [95% CI 0·52–0·91]; p=0·0090). The most frequently reported 
grade 3 or worse treatment-related adverse events were diarrhoea (six [3%] of 221 in the nivolumab group vs two [2%] 
of 111 in the placebo group) and infusion-related reaction (six [3%] vs none). Serious adverse events occurred in 
90 (41%) patients in the nivolumab group and 49 (44%) patients in the placebo group. There were no treatment-
related deaths in either group.
Interpretation Nivolumab represents a treatment that might be beneficial to patients with malignant mesothelioma 
who have progressed on first-line therapy.
Funding Stand up to Cancer–Cancer Research UK and Bristol Myers Squibb.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Malignant mesothelioma is a universally lethal cancer 
that is usually caused by exposure to asbestos fibres. It 
commonly arises in the thoracic parietal pleura or, less 
frequently, in the abdominal peritoneal lining, in the sac 
surrounding the heart, and the testes. Mesothelioma 
comprises three principal histological subtypes that are 
associated with decreasing survival: epithelioid, biphasic, 
and sarcomatoid. A pressing unmet need remains for 
new treatments in the relapsed mesothelioma setting.1 
Following the approval of pemetrexed and cisplatin for 
the treatment of pleural mesothelioma in 2004,2 no 
randomised phase 3 trial assessing any novel drug or 
combination of drugs has yet shown an improvement in 
overall survival3,4 in patients with malignant mesothelioma 
following disease progression.
Mesotheliomas express PD-L1 in a minority of 
patients.5,6 Promising clinical activity of nivolumab, a 
fully humanised, IgG4, PD-1-immune checkpoint inhi-
bitor antibody, has been reported in phase 2 trials of 
patients with malignant pleural mesothelioma.7–9 In the 
MERIT trial,7 nivolumab was associated with a median 
overall survival of 17·3 months (95% CI 11·5–not reached), 
median progression-free survival of 6·1 months (95% CI 
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2·9–9·9), and a response rate of 26% in patients with 
advanced or metastatic malignant pleural mesothelioma, 
leading to its approval in Japan. In the CheckpOiNt 
Blockade For the Inhibition of Relapsed Mesothelioma 
(CONFIRM) trial we aimed to evaluate the efficacy of 
nivolumab on overall survival and progression-free 
survival in patients with malignant mesothelioma whose 
disease had progressed following at least one course of 
platinum-based chemotherapy.
Methods
Study design and participants
This multicentre, double-blind, placebo-controlled, 
parallel group, randomised phase 3 trial was designed by 
the lead authors in collaboration with the sponsor 
(University of Southampton, Southampton, UK) and done 
in 24 hospitals in the UK (appendix p 50). Patients (aged 
≥18 years) with histologically confirmed pleural of 
peritoneal mesothelioma of any subtype, who had received 
at least one course of platinum-based chemotherapy and 
had subsequently had radiological evidence of disease 
progression, an Eastern Cooperative Oncology Group 
(ECOG) performance status score of 0 or 1, measurable 
disease according to modified Response Evaluation 
Criteria in Solid Tumors (RECIST) or RECIST version 1.1, 
and archival tumour biopsy for biomarker analyses were 
eligible for enrolment into the CONFIRM trial. Patients 
also had to meet the following laboratory criteria: white 
blood cell count of at least 2 × 10⁹ cells per L, neutrophil 
count at least 1·5 × 10⁹ cells per L, platelet count at least 
100 × 10⁹ per L, haemoglobin concentration at least 90 g/L, 
serum creatinine concentration of up to 1·5 × the upper 
limit of normal (ULN) or creatinine clearance higher than 
50 mL/min (using the Cockcroft-Gault formula), aspartate 
aminotransferase concen tration up to 3 × ULN or alanine 
aminotransferase concentration up to 3 × ULN (if both are 
assessed, both need to be up to 3 × ULN), and total 
bilirubin concentration up to 1·5 × ULN (except patients 
with Gilbert syndrome, who had to have total bilirubin 
<5·13 μmol/L). Patients were approached in the hospital 
setting by research staff. There was no restriction on the 
number of previous therapies received. Key exclusion 
criteria included previous treatment with an immune 
checkpoint inhibitor, uncontrolled metastasis involving 
the CNS, and autoimmune disease. The complete 
eligibility criteria are provided in the study protocol 
(appendix). Median survival with no additional treatment 
was expected to be approximately 6 months for eligible 
patients.3
The study protocol was approved by the West Midlands, 
Edgbaston Research Ethics Committee (16/WM/0472; 
appendix p 67). The study was done in accordance with 
the provisions of the Declaration of Helsinki and Good 
Clinical Practice guidelines as defined by the International 
Conference on Harmonisation. Written informed consent 
was obtained from all patients before enrolment.
Randomisation and masking
Participants were randomly assigned (2:1) to receive either 
nivolumab (nivolumab group) or placebo (placebo group). 
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Research in context
Evidence before this study
We searched MEDLINE from Jan 1, 2009, to Dec 31, 2020, for 
clinical trials using the terms “mesothelioma”, “relapsed”, or 
“pleural”, and “peritoneal”, “phase III”, “programmed death-1 or 
PD-1”, “placebo”, “nivolumab”, without any language 
restrictions. This search revealed no evidence of any published 
double-blind, phase 3, trial of an anti-PD-1 checkpoint inhibitor 
in patients with relapsed mesothelioma. Previous single-group 
phase 2A studies of nivolumab and other anti-PD-1 inhibitors 
have shown some clinical activity in this setting (level 2b 
evidence). However, no phase 3 trial has evaluated an anti-PD-1 
immune checkpoint inhibitor as monotherapy versus placebo 
(ie, level 1A evidence). No randomised phase 3 trials have 
enrolled patients with peritoneal mesothelioma. PD-L1 has 
been shown to be a useful predictive biomarker for stratifying 
therapy with an anti-PD-1 inhibitor (eg, in non-small-cell lung 
cancer). No study has yet done a double-blind analysis of PD-L1 
to determine its prognostic or predictive value for 
mesothelioma in a placebo-controlled, randomised, 
phase 3 trial in this setting.
Added value of this study
To our knowledge, the CONIFRM trial is the first randomised, 
phase 3 study to show improved overall survival in patients 
with relapsed malignant pleural and peritoneal mesothelioma. 
CONFIRM also met its co-primary endpoint of progression-free 
survival, with an acceptable level of safety and tolerability. 
PD-L1 was not found to be predictive or prognostic in the 
CONFIRM trial, highlighting the need for other predictors of 
efficacy for this drug class in mesothelioma. CONFIRM builds on 
three phase 2 clinical trials in the relapsed setting that showed 
promising single agent efficacy.
Implications of all the available evidence
The absence of an international standard of care or evidence for 
improved survival conferred by any drug in relapsed 
mesothelioma underpinned the design of the CONFIRM trial, 
with the goal of determining the specific efficacy of the 
anti-PD1 inhibitor nivolumab versus placebo in patients with 
either pleural or peritoneal mesothelioma of any histology. 
This study confirms nivolumab as an effective treatment that 
could be a new option in patients with relapsed mesothelioma. 
Efforts to identify predictive biomarkers of nivolumab are 
warranted. 
See Online for appendix
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Randomisation was done after baseline measures were 
recorded and successful screening with an inter active 
web response system. The randomisation sequence was 
generated with Alea. Patients were stratified according to 
epithelioid versus non-epithelioid histology, with random 
block sizes of 3 and 6. Treating clinicians and participants 
were masked to group allocation, but unmasking could be 
requested by the treating clinician following disease 
progression.
Procedures
A flat dose of 240 mg of nivolumab or placebo was 
administered intravenously over 30 min every 2 weeks. 
Treatment was continued until disease progression, 
withdrawal from treatment, or for a maximum of 
12 months, whichever occurred first. The key reason for 
the 12-month cap was based on the expected magnitude of 
both progression-free survival (median 3 months) and 
overall survival (median 6 months) durations, which are 
short for patients with mesothelioma in the relapsed 
treatment setting, and agreed as a pragmatic cap with 
Bristol Myers Squibb (the supplier of nivolumab). Dose 
delays were permitted for up to 4 weeks from the previous 
dose. Criteria for dose delay included any grade 2 non-skin, 
drug-related adverse events; any grade 3 skin drug-related 
adverse events; and any grade 3 drug-related laboratory 
abnormality adverse events. Treatment interruptions were 
permitted; restarting infusion was recommended for 
grade 2 symptoms, but discontinuation was recommended 
for grade 3 adverse events or worse. Full requirements for 
treatment delay or discontinuation because of treatment-
related adverse events are specified in the protocol. 
Reduction in the treatment dose was not permitted.
Participants were assessed with CT scans on day 1 of 
each 2-week cycle and 4 weeks after treatment discon-
tinuation. CT scans were not centrally reviewed. Adverse 
events were assessed at day 1 of each cycle, 4 weeks after 
discontinuation, and then at 100 days, and up to 100 days 
after treatment discontinuation, and graded using the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events version 4.03. Laboratory parameters 
(serum chemistry, full blood count, liver function tests, 
and thyroid function tests) were assessed on day 1 of each 
cycle until disease progression and 4 weeks after 
treatment discontinuation.
PD-L1 protein expression was evaluated retrospectively 
in pretreatment tumour-biopsy specimens with a 
validated automated immunohistochemical assay that 
used a rabbit monoclonal antihuman PD-L1 antibody 
(clone 22-C3) according to guidelines laid out in 
accordance with PD-L1 immunohistochemistry 22C3 
pharmDx (Agilent, Santa Clara, CA, USA). Evaluation 
was independently validated by a consultant histo patho-
logist (CR) and advanced biomedical scientist (PWJ). 
Samples were categorised as positive for PD-L1 when the 
staining of the tumour cell membrane (at any intensity) 
was observed at a prespecified expression threshold of 
1% of cells in a section that included at least 100 evaluable 
tumour cells.
Outcomes
The co-primary endpoints were progression-free survival 
(time from randomisation to disease progression 
according to masked investigator assessment or death, 
whichever occurred first) and overall survival (time from 
randomisation to death from any cause). The co-primary 
endpoints were monitored every 3 months following 
discontinuation of treatment. Secondary endpoints were 
overall response to treatment, defined as either complete 
or partial response according to masked investigator 
assessment, stable disease or progressive disease; 
12-month overall survival and progression-free survival; 
safety; and efficacy (for progression-free survival and 
overall survival) according to tumour PD-L1 tumour 
proportion score. Quality of life (EQ-5D) and cost per 
QALY data were collected as part of the trial but are not 
reported here to allow for full follow-up to take place.
Statistical analysis
Sample size was based on a hazard ratio (HR) of 0·7 for 
overall survival (equivalent to an improvement in median 
overall survival from 6·0 to 8·5 months), 80% power, 
4 years of recruitment, and 6 months of follow-up. This 
led to a target sample size of 336 participants (291 events). 
A two-sided α of 0·04 was chosen based on interim 
analyses for efficacy for overall survival. One formal 
interim analysis for futility was carried out after 74 (25%) 
overall survival events had occurred in June, 2019, 
(median follow up 5·09 months (IQR 3·91–6·90). The 
study continued as planned after this interim analysis.
Almost 2 years into recruitment (Feb 14, 2019; protocol 
amendment 6), progression-free survival was added as a 
co-primary endpoint due to concerns that immuno-
therapy might be increasingly used off-study following 
progression, thus affecting the estimate of the effect of 
nivolumab on overall survival. Following the addition of 
progression-free survival as a co-primary endpoint, an α 
of 0·04 was maintained for overall survival, based on a 
hierarchical testing procedure,10 designed to maintain an 
overall α of 0·05 across the co-primary endpoints. This 
procedure used two α values to determine significance 
for progression-free survival depending on whether 
overall survival was significant (α 0·05) or not (α 0·01). 
The sample size of 336 participants gave more than 
80% power for a HR of 0·65 for progression-free survival 
(with α 0·01). This change was approved by the 
independent masked Trial Steering Committee and was 
included in a protocol amendment 6.
On Jan 13, 2020, it was agreed, and approved by the 
independent masked Trial Steering Committee, that the 
preplanned interim efficacy and futility analyses should 
be removed (approximately 3 months before the 
anticipated end of recruitment; protocol amendment 7; 
June 11, 2020). The efficacy analysis was based on PD-L1 
For more on Alea see 
https://www.aleaclinical.eu/
Articles
4 www.thelancet.com/oncology   Published online October 14, 2021   https://doi.org/10.1016/S1470-2045(21)00471-X
status, and recruitment was almost complete once 
sufficient samples were obtained and analysed. Interim 
futility analyses were removed due to them being done 
too near to or after the end of recruitment (as a 
consequence of faster than anticipated recruitment), 
restricting their perceived value. No other modifications 
were made to the study.
All statistical analyses were done with Stata (version 16.0). 
Investigator-reported progression-free survival and overall 
survival were analysed with a Cox proportional hazards 
model, adjusted for epithelioid type (because this was a 
stratification factor). Significance thresholds were 0·04 for 
overall survival, and either 0·05 if overall survival was 
significant or 0·01 if overall survival was not significant for 
progression-free survival. Survival curves for each group 
were estimated with the Kaplan-Meier method, and non-
proportionality was assessed visually. Survival rates were 
derived from the Kaplan-Meier estimates. Prespecified 
sensitivity analyses were done to evaluate the predictive 
role of pre-study status with respect to PD-L1 expression 
defined as either positive or negative, using a group by 
expression interaction term in the Cox model. Response 
rates were compared with a crude odds ratio test (ie, no 
adjustment factors). Median time to onset of treatment-
related adverse events and median time to resolution of 
treatment-related adverse events were assessed in a post-
hoc analysis using the observed median time.
Both co-primary and secondary efficacy analyses and 
safety analyses include all participants who were 
randomly assigned. The only exception is for the PD-L1 
analysis, for which only patients with assessable tissue 
samples were included. Analysis was done based on the 
treatment policy estimand, in which participants were 
analysed according to the group they were randomly 
assigned to and regardless of other treatments, such as 
off-trial immunotherapy (equivalent to the intention-to-
treat principle). A prespecified analysis of progression-
free survival and overall survival across prespecified 
baseline characteristics with forest plots was done. 
Median time to response and duration of response 
were included as post-hoc analyses. A prespecified 
efficacy analysis by PD-L1 subgroups were assessed for 
progression-free survival and overall survival.
221 assigned to the nivolumab group
332 enrolled and randomly assigned
532 patients assessed for eligibility
200 excluded 
92 did not meet inclusion criteria
14 declined to participate
60 declined to specify reason
34 other reasons 
221 included in the analysis





8 withdrawal by investigator






1 lost to follow-up
17 other reasons
111 assigned to the placebo group
111 included in the analysis





3 withdrawal by investigator












Median age, years (IQR) 70 (65–74) 71 (65–76)
Sex 
Male 167 (76%) 86 (78%)
Female 54 (24%) 25 (23%)
ECOG performance status score
1 177 (80%) 89 (80%)
0 44 (20%) 22 (20%)
Smoking status
Ex-smoker 105 (48%) 52 (47%)
Non-smoker 100 (45%) 52 (47%)
Current smoker 15 (7%) 6 (5%)
Missing 1 (<1%) 1 (1%)
Site of mesothelioma
Pleural 211 (95%) 105 (95%)
Non-pleural 10 (5%) 6 (5%)
PD-L1 status
<1% (negative) 101 (46%) 65 (59%)
≥1% (positive) 60 (27%) 26 (23%)
Missing 60 (27%) 20 (18%)
Histology
Epithelioid 195 (88%) 98 (88%)
Non-epithelioid 26 (12%) 13 (12%)
Asbestos exposure 
Yes 150 (68%) 80 (72%)
No 65 (29%) 30 (27%)
Missing 6 (3%) 1 (1%)
Line of treatment
Second line 63 (29%) 37 (33%)
Third line 124 (56%) 66 (60%)
Later than third line 34 (15%) 8 (7%)
Time since mesothelioma diagnosis 
Median time since diagnosis, 
months (IQR)
17·8 (11·7–27·4) 17·7 (10·9–25·7)
Missing 0 1 (1%)
Data are n (%), unless otherwise stated.
Table 1: Baseline characteristics
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This trial is registered with ClinicalTrials.gov, 
NCT03063450.
Role of the funding source
The funder of the study, Cancer Research UK–Stand Up 
to Cancer, had no role in trial design, data collection, data 
analysis, data interpretation, or writing of the report. 
Bristol Myers Squibb provided nivolumab.
Results
Between May 10, 2017, and March 30, 2020, we enrolled 
332 participants, of whom 221 (67%) were assigned to the 
nivolumab group and 111 (33%) to the placebo group 
(figure 1). Recruitment was paused on March 30, 2020, 
when 332 people had been recruited, due to the COVID-19 
pandemic. Following a COVID-19 impact review, the 
Independent Data Monitoring Committee and Trial 
Steering Committee did not require the trial to reopen to 
recruitment for the remaining four patients after the UK 
COVID-19 lockdown (March to June, 2020). This decision 
was made primarily due to the trial recruiting ahead of 
time, allowing for longer follow-up to reach the required 
number of events. Following a meeting in August, 2020, 
the Independent Data Monitoring Committee recom-
mended the immediate release of preliminary data, 
approximately 1 year earlier than planned, for investigator-
reported progression-free survival and overall survival. 
This decision was ratified by the Trial Steering Committee. 
We report the results of the preliminary analysis based on 
data collected from May 10, 2017, to Jan 4, 2021. All 
332 participants were included in the analysis of the 
co-primary outcomes. The median follow-up (of those 
still alive on Jan 4, 2021) was 11·6 months (IQR 7·2–16·8).
The baseline characteristics of the patients are shown in 
table 1. The median age of the patients was 70 years 
(IQR 65–75). 253 (76%) of the 332 patients were male; 
266 (80%) patients had an ECOG performance status 
score of 1; 316 (95%) patients had pleural mesothelioma; 
293 (88%) patients had epithelioid histology; and 230 (69%) 
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Nivolumab group median 3·0 months (95% CI 2·8–4·1)
Placebo group median 1·8 months (95% CI 1·4–2·6)
Adjusted HR  0·67 (95% CI 0·53–0·85); p=0·0012
Nivolumab group median 10·2 months (95% CI 8·5–12·1)
Placebo group median 6·9 months (95% CI 5·0–8·0)
Adjusted HR 0·69 (95% CI 0·52–0·91); p=0·0090
Figure 2: Kaplan–Meier curves of progression-free survival (A) and overall survival (B)
HR=hazard ratio. Shaded areas represent 95% CIs.
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were available for 252 (76%) patients, of whom 86 (34%) 
were positive and 166 (66%) negative. All of the enrolled 
patients had received platinum-based therapy previously; 
322 (97%) had received pemetrexed (appendix p 66).
217 (98%) of 221 patients in the nivolumab group 
and 110 (99%) of 111 patients in the placebo group 
received at least one dose of treatment. A median of six 
doses (IQR 3–12) of nivolumab and four doses of placebo 
(3–7) were administered. At least one dose delay occurred 
in 96 (44%) of the 217 patients in the nivolumab group 
and 34 (31%) of the 110 patients in the placebo group. 
Overall, 144 (8%) of the 1872 treatment cycles in the 

































































































































































































































Figure 3: Forest plots showing subgroup analyses of progression-free survival (A) and overall survival (B)
HR=hazard ratio. NE=not estimable.
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nivolumab group had delays and 45 (6%) of the 
747 treatment cycles in the placebo group had delays. Of 
the participants who had dose delays, most patients had 
only one dose delay (66 [69% of 96 patients in the 
nivolumab group and 26 [77%] of 34 patients in the 
placebo group), ranging from 1 to 263 days in duration 
(appendix p 66).
12 (6%) of 217 patients in the nivolumab group and 
three (3%) of 110 patients in the placebo group completed 
protocol treatment. After discontinuation of treatment, 
77 (35%) of 217 patients in the nivolumab group and 
39 (35%) of 110 patients in the placebo group received 
subsequent systemic cancer therapy. In the placebo 
group, 12 (11%) of 111 patients received nivolumab 
following unmasking (requested by the clinical team 
primarily following progression).
At the time of the preliminary analysis database lock 
(Jan 4, 2021), a recorded date of death had been reported 
for 210 (63%) of the 332 participants who had undergone 
randomisation (72% of the 291 deaths required for the 
final analysis). 299 (90%) had investigator-reported 
dates of progression (more than the target of 284 [86%] 
patients). Median investigator-reported progression-
free survival was 3·0 months (95% CI 2·8–4·1; events 
reported for 198 [90%] of 221 patients) in the nivolumab 
group, compared with 1·8 months (1·4–2·6; events 
reported for 101 [91%] of 111 patients) in the placebo 
group (adjusted HR 0·67 [95% CI 0·53–0·85]; 
p=0·0012; significance threshold of 0·05; figure 2A). 
Progression-free survival at 1 year was 14·2% (95% CI 
9·9–19·3) in the nivolumab group versus 7·2% 
(3·1–13·8) in the placebo group. Progression-free 
survival in the prespecified subgroups of patients with 
epithelioid or non-epithelioid histology and by PD-L1 
positivity status are shown in the appendix (pp 51–52, 55). 
Figure 3A shows a forest plot of progression-free 
survival across baseline characteristics.
Median overall survival was 10·2 months (95% CI 
8·5–12·1; deaths reported in 134 [61%] of 221 patients) in 
the nivolumab group compared with 6·9 months 
(5·0–8·0; deaths reported in 76 [68%] of 111 patients) in 
the placebo group (adjusted HR 0·69 [95% CI 0·52–0·91]; 
p=0·0090; significance threshold of 0·04; figure 2B). 
Overall survival at 1 year was 43·4% (95% CI 36·3–50·4) 
in the nivolumab group versus 30·1% (21·0–39·6) in the 
placebo group. Overall survival in the prespecified 
subgroups of patients with epithelioid or non-epithelioid 
histology and by PD-L1 positivity status are shown in the 
appendix (pp 53–54, 56). Figure 3B shows a forest plot of 
overall survival across baseline characteristics.
For both progression-free survival and overall survival, 
the Kaplan-Meier plots were assessed visually for 
proportional hazards. Although there was a delay in 
divergence of the curves immediately following random-
isation, the research team felt there to be no strong 
evidence of non-proportionality.
The overall response rate was significantly higher in 
the nivolumab group (25 [11%] of 221 patients had a 
partial response) than in the placebo group (one [1%] of 
111 patients had a partial response; odds ratio 14·0 
[95% CI 2·4–not estimable, p=0·00086; table 2). The 
median time to response was 84 days (95% CI 81–145) in 
the nivolumab group, and the median duration of 
response was 143 days (92–211). One (1%) patient in the 
placebo group partially responded with a time to response 
of 132 days, lasting a duration of 212 days.
252 (76%) of the 332 randomly assigned patients had 
quantifiable PD-L1 expression. On the basis of a positivity 
threshold of 1%, there was no evidence of PD-L1 expression 
being predictive of response to treatment for either overall 
survival (HR for interaction 1·16 [95% CI 0·56–2·40]; 
p=0·70) or progression-free survival (HR for interaction 
1·55 [0·85–2·83]; p=0·16). A sensitivity analysis revealed 
no interaction between PD-L1 expression and clinical 
outcome (appendix pp 55–56).
Adverse events leading to treatment discontinuation 
occurred in 30 (14%) of 217 patients in the nivolumab 
group compared with three (3%) of 110 patients in the 
placebo group (appendix p 64). The most common 
adverse events that led to treatment discontinuation in 
the nivolumab group were infusion-related reactions 
(four [13%]) and diarrhoea (three [10%]). In the control 
group one (33%) patient discontinued due to pneumonia 
and one (33%) due to hyponatraemia; the adverse event 
was not reported for the third patient.
Serious adverse events occurred in 90 (41%) of 
221 patients in the nivolumab group and 49 (44%) of 
111 patients in the placebo group. The most frequent 
serious adverse events were dyspnoea (18 [8%] of 
221 patients in the nivolumab group vs ten [9%] of 
111 patients in the placebo group), pneumonia (14 [6%] 
vs six [5%]) and lower respiratory tract infection 
(eight [4%] vs eight [7%]; appendix pp 57–60). Causes of 
death related to any serious adverse events are 
summarised in the appendix (p 65). There were no 
treatment-related deaths in either group.























11 (18%) 25 (25%) 51 (23%) 7 (27%) 29 (45%) 46 (41%)
Stable 
disease
34 (57%) 50 (50%) 117 (53%) 14 (54%) 33 (51%) 54 (49%)
Partial 
response
7 (12%) 10 (10%) 25 (11%) 1 (4%) 0 1 (1%)
Not 
evaluable
0 2 (2%) 2 (1%) 0 0 0
Missing 8 (13%) 14 (14%) 26 (12%) 4 (15%) 3 (5%) 10 (9%)
Data are n (%). *All patients are included, including those with missing PD-L1 status.
Table 2: Responses to nivolumab and placebo
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Treatment-related adverse events, including haem-
atological and non-haematological events, occurred in 
163 (74%) of 221 patients in the nivolumab group and 
62 (56%) of 111 patients in the placebo group (table 3; 
appendix pp 61–63) No grade 5 events were reported in 
either group. The most frequently reported grade 3 
or worse treatment-related adverse events diarrhoea 
(six [3%] of 221 in the nivolumab group vs two [2%] 
of 111 in the placebo group), and infusion-related reaction 
(six [3%] vs none).
Treatment-related serious adverse events also occurred 
in 28 (13%) of 221 patients in the nivolumab group and 
eight (7%) of 111 patients in the placebo group. Diarrhoea 
(five [2%] of 28 patients in the nivolumab group and 
three [3%] of eight patients in the placebo group) and 
infusion-related reactions (four [2%] of 28 patients in the 
nivolumab group and one [1%] of eight patients in the 
placebo group) were the most frequent treatment-related 
serious adverse events.
The most frequently reported immune-related treatment 
related adverse events of any grade were gastrointestinal 
(76 [34%] of 221 patients in the nivolumab group vs 
29 [26%] of 111 patients in the placebo group) and skin 
(51 [23%] in the nivolumab group vs 14 [13%] in the placebo 
group). Median time to onset of treatment-related adverse 
events was 15 days (IQR 4–31) across categories in the 
nivolumab group and 11 days (2–26) in the placebo group.
The median time to resolution of treatment-related 





Grade 1–2 Grade 3 Grade 1–2 Grade 3
Anaemia 5 (2%) 1 (1%) 0 0
Thrombocytopenia 0 1 (1%) 0 0
Cardiac dysfunction 0 1 (1%) 0 0
Tachycardia 0 0 0 1 (1%)
Hypothyroidism 10 (5%) 1 (1%) 1 (1%) 0
Macular oedema 0 0 0 1 (1%)
Abdominal pain 2 (1%) 1 (1%) 1 (1%) 0
Ascites 1 (1%) 1 (1%) 0 0
Colitis 1 (1%) 3 (1%) 0 0
Colitis microscopic 0 1 (1%) 0 0
Diarrhoea 29 (13%) 6 (3%) 8 (7%) 2 (2%)
Nausea 32 (15%) 0 9 (8%) 0
Stomatitis 4 (2%) 2 (1%) 1 (1%) 0
Vomiting 9 (4%) 1 (1%) 4 (4%) 0
Chest pain 0 1 (1%) 0 0
Fatigue 59 (27%) 1 (1%) 20 (18%) 1 (1%)
Generalised oedema 0 1 (1%) 0 0
Malaise 1 (1%) 0 0 1 (1%)
Autoimmune 
hepatitis
0 2 (1%) 0 0
Hepatotoxicity 1 (1%) 1 (1%) 0 0
Infusion-related 
reaction












5 (2%) 4 (2%) 0 0
Blood bilirubin 
increased
4 (2%) 1 (1%) 1 (1%) 0
Blood creatinine 
increased
1 (1%) 0 2 (2%) 1 (1%)





Grade 1–2 Grade 3 Grade 1–2 Grade 3




0 1 (1%) 0 0
Lipase increased 0 1 (1%) 0 0
Hyponatraemia 0 0 0 1 (1%)
Arthralgia 13 (6%) 1 (1%) 5 (5%) 0
Arthritis 2 (1%) 1 (1%) 1 (1%) 0
Back pain 3 (1%) 1 (1%) 2 (2%) 0
Myositis 0 0 0 0
Ataxia 0 1 (1%) 0 0
Carpal tunnel 
syndrome
0 1 (1%) 0 0
Facial paralysis 0 1 (1%) 0 0
Headache 4 (2%) 1 (1%) 2 (2%) 0
Tremor 1 (1%) 1 (1%) 0 0
Anxiety 0 1 (1%) 0 0
Prostatism 0 0 0 1 (1%)
Chronic obstructive 
pulmonary disease
0 1 (1%) 0 0
Dyspnoea 15 (7%) 2 (1%) 5 (5%) 1 (1%)
Dyspnoea exertional 0 1 (1%) 0 0
Immune-mediated 
pneumonitis
0 1 (1%) 0 0
Pneumonitis 0 1 (1%) 0 0
Pulmonary 
embolism
1 (1%) 1 (1%) 0 0
Erythema 1 (1%) 1 (1%) 0 0
Pruritus 24 (11%) 0 10 (9%) 0
Data are n (%). Two grade 4 events were reported in the nivolumab group: 
one (1%) patient had grade 4 gamma-glutamyltransferase increase and 
one (1%) patient had grade 4 myositis. There were no grade 4 events reported in 
the placebo group.
Table 3: Treatment-related adverse events
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group and 5 days (1–22) in the placebo group. The median 
time to onset of treatment-related adverse pulmonary 
events was 84 days (IQR 42–126) with a median time of 
resolution of 56 days (2–110) in the nivolumab group; 
there were no events in the placebo group. There were no 
recurrences of pneumonitis in both groups.
Discussion
The CONFIRM trial showed longer progression-free 
survival and overall survival with nivolumab compared 
with placebo in patients with relapsed mesothelioma. 
To our knowledge, CONFIRM is the first randomised 
phase 3 trial to show significantly improved overall 
survival for patients with relapsed mesothelioma 
following platinum-based doublet chemotherapy. Cross-
over to immuno therapy in the placebo group was 
infrequent, probably because of the general scarcity of 
availability of off-label immune checkpoint inhibitors in 
the UK during this study. CONFIRM justifies the use of 
single drug anti-PD-1 inhibition in patients who have 
received first-line platinum-doublet therapy. These 
results also support the findings of other single group 
phase 1 trials, including the MERIT trial7 which led to the 
approval of nivolumab in Japan in 2018. The much larger 
size of the CONFIRM cohort, might account for any 
differences in outcome compared with the MERIT trial.
Patients, particularly those in the placebo group, with 
rapid disease progression and clinical deterioration were 
unable to attend a CT scan, especially in cases where this 
required longer travel (sometimes with a substantial 
distance) to the CONFIRM trial centre.
A key limitation of the study was the absence of centrally 
reviewed radiology, despite the use of progression-free 
survival as a co-primary endpoint; the study was not 
funded to include a central review. Radiological inter-
pretation of progression (or response) in patients with 
mesothelioma is challenging, with the accuracy of assess-
ment dependent on the use of modified RECIST criteria. 
Another limitation of CONFIRM was that most of the 
recruited patients were in the third line setting, given the 
current the absence of a post-platinum approved therapy. 
This was in part due to patients having had rechallenge 
platinum-based therapy or vinorelbine as a second-line 
treatment. Whether the efficacy of nivolumab could have 
differed if this study had been designed for a strictly 
second-line population remains unknown. For this 
reason, the results can only be extrapolated to the second-
line setting.
This trial enrolled patients with peritoneal meso-
thelioma; there were several reasons for this decision. 
First, this group of patients is under-served in terms of 
access to novel drugs. Second, there are no data, to our 
knowledge, on the efficacy of single-drug anti-PD-1 or 
anti-PD-L1 immunotherapy in patients with relapsed 
peritoneal mesothelioma; this is probably because of the 
very small number of patients with the disease, which 
would make a placebo-controlled randomised trial in this 
group very challenging. Third, given the similar genomic 
landscape of both pleural and peritoneal mesothelioma 
(copy number-driven somatic alterations including high 
BAP1 and CDKN2A inactivation frequency), there was no 
expectation of widely differing responses to anti-PD-1 
checkpoint inhibition between these subtypes. The 
prognostic variation within the pleural subgroup (based 
on histology and genotype) is probably significantly higher 
than between pleural and peritoneal mesothelioma based 
on the DETERMINE trial.4
For the most common immune-related treatment 
related adverse events, nivolumab had additional toxicity 
in the order of 10%. For other treatment related adverse 
events, nivolumab was primarily seen to cause an 
increase in fatigue, diarrhoea, nausea, and rash, but the 
increases were generally modest (5–10%) compared with 
placebo.
The PROMISE meso trial,11 which reported its results 
in 2020, did not show superiority of the PD-1 immune 
checkpoint inhibitor, pembrolizumab, compared with 
chemotherapy (vinorelbine or gemcitabine) for overall 
survival. The choice of either vinorelbine or gemcitabine 
was based on previous single-group phase 2 studies, 
showing variable levels of useful activity.12,13 So far, no 
randomised trial of vinorelbine has been reported in the 
relapsed setting. The VIM randomised phase 2 trial14 of 
vinorelbine versus active symptom control was reported 
to meet its primary endpoint of significantly improved 
progression-free survival. Gemcitabine showed a 
promising signal of activity in the post first-line chemo-
therapy setting as switch maintenance in the randomised 
phase 2 trial NVALT19.15 On the basis of the absence of a 
licenced therapy in the relapsed setting, placebo was 
chosen as the control for the CONFIRM trial.
The DETERMINE trial9 was a placebo-controlled, 
randomised, phase 2 trial of the anti-CTLA-4 immune 
checkpoint inhibitor, tremelimumab, in patients with 
relapsed mesothelioma. There was no effect on overall 
survival; however, ipilimumab (anti-CTLA-4) in combi-
nation with nivolumab versus nivolumab alone probably 
showed synergy in the relapsed setting in the non-
comparative, randomised, phase 2 MAPS2 trial.8 
Ipilimumab and nivolumab showed superiority com-
pared with pemetrexed–platinum doublet in the first line 
setting in the Checkmate 743 phase 3 trial,16 with an 
overall survival HR of 0·74; ipilimumab and nivolumab 
combination therapy has since been approved by the US 
Food and Drug Administration and the European 
Medicines Agency (Oct 2, 2020) as first-line treatment of 
patients with unresectable malignant pleural meso-
thelioma. However, a subgroup analysis showed a larger 
overall survival benefit with nivolumab plus ipilimumab 
compared with chemotherapy for patients with non-
epithelioid histology (HR 0·46 [95% CI 0·31–0·68]) than 
those with epithelioid histology (0·86 [0·69–1·08]),16 
although the study was not powered to test superiority 
within subgroups.
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By contrast, our prespecified subgroup analysis seemed 
to suggest superiority for nivolumab versus placebo in 
patients with epithelioid disease who had previously 
received platinum doublet regimens. This finding was 
not observed in patients with non-epithelioid meso-
thelioma, although this could be accounted for by the 
small number of patients with this relatively rare 
histological subtype, and the immature number of 
survival events in that subgroup at the time of this 
analysis. Furthermore, selection bias of patients with 
non-epithelioid meso theliomas could arise if they did not 
survive long enough to enrol in the CONFIRM trial, 
highlighting the importance of treating these patients as 
early as possible with immunotherapy, as suggested by 
the Checkmate 743 trial.16
PD-L1 is an established predictive biomarker for 
immune checkpoint therapy in non-small-cell lung 
cancer.17 Robust evidence for PD-L1 as a predictive factor 
for PD-1 inhibition in mesothelioma is scarce.11 
Overexpression of PD-L1 has been associated with a poor 
prognosis.18 Using the Dako 22C3 PD-L1 tumour 
proportion score above 1%, we found no evidence to 
support a role for PD-L1 as a predictive biomarker. 
However, caution is required in interpretation due to 
the immaturity of the data and the low PD-L1 expres-
sion (consistent with other studies employing the 
22C3 antibody),6 which is underpowered to detect a 
statistically significant effect at more than 1% or more 
than 50% (appendix pp 52, 54–56). For this reason, use of 
a different threshold (eg, >50%) was not applied. 
Although pretreatment biopsies were used, there is no 
evidence for statistically significant changes in PD-L1 
expression longitudinally following platinum-based 
chemotherapy.19 PD-L1 evaluation was done in 76% of 
participants in CONFIRM, in part due to diagnostic 
biopsies being either unevaluable or missing at the time 
of collection (which in some cases was after a substantial 
period following enrolment).
The cellular and molecular determinants of response 
to PD-1 checkpoint inhibition in mesothelioma remain 
elusive. Accordingly, extensive translational research 
studies have been initiated in CONFIRM to explore the 
genomic and tumour microenvironmental interactions 
with outcome and to understand the molecular deter-
minants of sensitivity in mesothelioma. We will continue 
to follow-up participants in the CONFIRM trial for 
overall survival and progression-free survival, until the 
original planned study end (expected July, 2021). A final 
analysis is planned following com pletion of the study, 
which will include an updated analysis and a health 
economics analysis.
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